TICKERNERD
Menu
OMOMHealthcare · Medical Devices

OM Stock Forecast: Outset Medical, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$4.21
−2.09% on the day

The 3 Wall Street analysts covering Outset Medical, Inc. hold a median 12-month price target of $7 — +66.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$79.1M
Ticker Nerd rank
29 / 100
Median analyst target
$7.00
Analysts covering
3
Total return, dividends reinvested
1W
−6.7%
1M
+2.2%
YTD
+13.5%
1Y
−69.2%
From 52W high
−73.4%
From 52W low
+33.2%
$3
$16
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Outset Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
29 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
87
Size
78
Quality
61
Growth
58
Revisions
33
Value
28
Issuance
17
Volatility
11
Momentum
4

Accruals (87): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (4): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2$4$6$8$10$12$14$16Oct 25Jan 26Apr 26Jul 26OMHigh $10.00Median $7.00Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
2 Buy1 Hold0 Sell
Low $6.00Median $7.00High $10.00

The green dot is the last close — the median target sits +66.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Feb 2026BTIGMaintainsBuy$17 → $15
7 Jan 2026StifelMaintainsBuy—
16 Dec 2025BTIGReiteratesBuy—
11 Nov 2025BTIGMaintainsBuy—
11 Nov 2025RBC CapitalMaintainsSector Perform—
11 Nov 2025StifelMaintainsBuy—
19 Aug 2025RBC CapitalReiteratesSector Perform—
7 Aug 2025RBC CapitalMaintainsSector Perform—
21 May 2025RBC CapitalMaintainsSector Perform—
8 May 2025RBC CapitalMaintainsSector Perform—
7 Jan 2025RBC CapitalReiteratesSector Perform—
8 Aug 2024RBC CapitalDowngradeSector Perform—
8 Aug 2024TD CowenMaintainsBuy—
21 June 2024RBC CapitalUpgradeOutperform—
8 Apr 2024BTIGInitiatesBuy—
12 Jan 2024RBC CapitalDowngradeSector Perform—
4 Dec 2023Morgan StanleyMaintainsEqual-Weight—
14 Nov 2023Morgan StanleyMaintainsEqual-Weight—
13 Oct 2023B of A SecuritiesDowngradeUnderperform—
13 Oct 2023RBC CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

OM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Outset Medical, Inc. (OM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.8×

Cheaper than 81% of US stocks

Price / sales
0.7×

Cheaper than 78% of US stocks

Price / book
0.8×

Cheaper than 78% of US stocks

EV / EBITDA
−0.6×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
0.7%

Higher than 29% of US stocks

Earnings growth (YoY)
0.7%

Higher than 36% of US stocks

Gross margin
42.0%

Higher than 53% of US stocks

Operating margin
−49.6%

Higher than 17% of US stocks

Net margin
−63.1%

Higher than 9% of US stocks

Returns & dividend
Return on equity
−59.2%

Higher than 19% of US stocks

Return on assets
−15.5%

Higher than 22% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

OM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
OMOutset Medical, Inc.$79.1M
29
CVRXCVRx, Inc.$74.7M
34
RPIDRapid Micro Biosystems, Inc.$83.7M
32
SERASera Prognostics, Inc.$83.8M
40
MYOMyomo, Inc.$68.5M
45
NNOXNano-X Imaging Ltd.$67.6M
27
LUNGPulmonx Corp.$93.2M
74

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Outset Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OM news & analysis

Despite Fast-paced Momentum, Outset Medical (OM) Is Still a Bargain Stock

Zacks Investment Research · 18 Aug 2026positive

Zacks Investment Research reported that Outset Medical (OM) passed its "Fast-Paced Momentum at a Bargain" stock screen, indicating the stock has recently exhibited strong momentum while trading at reasonable prices.

Why it matters — An OM watcher would care because the screen suggests the company's stock combines recent upward momentum with an attractive valuation, which could draw further investor attention.

Outset Medical, Inc. (OM) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Outset Medical, Inc. released the transcript of its Q2 2026 earnings call, as published by Seeking Alpha. The transcript covers the company's quarterly financial results and management commentary.

Why it matters — OM watchers would care because the earnings call transcript provides direct insight into the company's latest quarterly performance and management's discussion for the period.

Outset Medical Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

Outset Medical reported second-quarter 2026 revenue of $31.6 million, up 1% year over year and 14% sequentially, citing commercial progress, improving margins, and a new $40 million refresh agreement with HCA Healthcare.

Why it matters — A viewer tracking Outset Medical would note the revenue growth and the new $40 million HCA Healthcare agreement as signs of commercial traction for the dialysis technology company.

Outset Medical, Inc. (OM) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 6 Aug 2026neutral

Outset Medical reported a second-quarter loss of $0.8 per share, wider than the Zacks Consensus Estimate of a $0.63 loss but narrower than the $0.84 loss a year ago. The company beat revenue estimates for the quarter.

Why it matters — OM watchers would monitor the results because the quarterly loss came in wider than consensus expectations even as the company exceeded revenue estimates and improved versus last year.

Outset Medical Reports Second Quarter 2026 Results

GlobeNewsWire · 6 Aug 2026neutral

Outset Medical, Inc. reported its financial results for the second quarter ended June 30, 2026, in an announcement dated August 6, 2026. The company was described as a medical technology company pioneering technology to improve clinical outcomes in dialysis with less cost and complexity.

Why it matters — The announcement provides OM watchers with the company's latest quarterly financial results, offering an update on its performance for the period.

FAQ

Frequently asked questions about OM stock

What is the OM stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Outset Medical, Inc. have a median 12-month price target of $7, with estimates ranging from $6 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OM stock a buy right now?

Of the 3 analysts covering Outset Medical, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Outset Medical, Inc. 29 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OM?

As at 22 Aug 2026, Outset Medical, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (87 of 100).

Will OM stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +66.3% from the last close, and Ticker Nerd's factor model ranks Outset Medical, Inc. 29 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OM stock forecast for 2030?

No analyst covering Outset Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $10 over the next 12 months.

How has OM stock performed over the past year?

Outset Medical, Inc. returned -69.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Outset Medical, Inc. do?

Outset Medical Inc. is a pioneering company in the medical technology field, primarily focusing on the development and commercialization of innovative dialysis solutions.

What is the latest news on OM?

The most recent item we track (Zacks Investment Research, 18 Aug 2026): "Despite Fast-paced Momentum, Outset Medical (OM) Is Still a Bargain Stock". Zacks Investment Research reported that Outset Medical (OM) passed its "Fast-Paced Momentum at a Bargain" stock screen, indicating the stock has recently exhibited strong momentum while trading at reasonable prices.

Company

About Outset Medical, Inc.

Outset Medical Inc. is a pioneering company in the medical technology field, primarily focusing on the development and commercialization of innovative dialysis solutions. Its flagship product, the Tablo Hemodialysis System, is designed to simplify dialysis treatments, whether in medical facilities or at home. The system integrates water purification with dialysate production, offering a seamless, all-in-one dialysis solution. This transformative approach aims to make dialysis more accessible and user-friendly for patients and healthcare providers. Outset Medical's advancements in the dialysis sector are significant, as they strive to redefine treatment standards and improve patient quality of life. Headquartered in the United States, Outset Medical continues to impact the healthcare industry by addressing the growing demand for efficient and scalable renal care solutions.

CEO Ms. Leslie L. Trigg · 310 employees · United States · https://www.outsetmedical.com